Physician profile
Mirna Abboud
NPI 1386938371
$2,117.12
in general payments reported to CMS, 2019-2025
34 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 84% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.40 · 2023: $268 · 2024: $783 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,075.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $323.06 | 2024-2025 | Calquence, Imfinzi, Enhertu |
| Sobi, INC | $288.45 | 2023-2025 | |
| Janssen Biotech, INC. | $181.28 | 2023-2025 | Darzalex, Carvykti, Erleada |
| Incyte Corporation | $177.58 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Aveo Pharmaceuticals, INC. | $105.55 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $88.50 | 2024 | Myrisk |
| Pfizer INC. | $76.10 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $68.62 | 2024-2025 | Keytruda, Keytruda Qlex, Reblozyl |
| Pharmaessentia USA Corporation | $68.05 | 2023-2024 | Besremi |
| Caris Mpi, INC. | $66.96 | 2025 | Mi Cancer Seek |
| Beone Medicines USA, INC. | $58.22 | 2025 | Tevimbra |
| Taiho Oncology, INC. | $57.11 | 2023-2024 | |
| Rigel Pharmaceuticals, INC. | $55.75 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Regeneron Healthcare Solutions, INC. | $49.57 | 2024-2025 | Lynozyfic, Libtayo |
| Immunocore Limited | $41.62 | 2025 | Kimmtrak |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $29.53 | 2024-2025 | |
| Daiichi Sankyo INC. | $29.28 | 2025 | Enhertu |
| Gilead Sciences, INC. | $28.52 | 2025 | Trodelvy |
| Myovant Sciences INC. | $27.93 | 2022 | |
| Abbvie INC. | $27.35 | 2025 | |
| Deciphera Pharmaceuticals INC. | $26.73 | 2024 | Qinlock |
| Bayer Healthcare Pharmaceuticals INC. | $23.74 | 2025 | |
| Emd Serono, INC. | $20.69 | 2025 | |
| Tolmar, INC. | $20.21 | 2025 | Eligard |
| Adc Therapeutics America, INC. | $19.94 | 2025 | |
| Tactile Systems Technology INC | $19.72 | 2025 | Flexitouch Plus, Nimbl |
| Sumitomo Pharma America, INC. | $19.27 | 2024 | Orgovyx |
| Boston Scientific Corporation | $18.95 | 2023 | Spaceoar Vue System - 10ml |
| Novartis Pharmaceuticals Corporation | $18.82 | 2025 | |
| Gt Medical Technologies, INC | $18.75 | 2025 | Gammatile |
| Coherus Oncology, INC. | $17.94 | 2024 | |
| Mirati Therapeutics, INC. | $16.44 | 2023 | Krazati |
| Seagen INC. | $13.47 | 2022 | |
| Pharmaand Gmbh | $13.42 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mirna Abboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.